Other
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK(TM) at the 2026 ASCO Annual Meeting
Fennec Pharmaceuticals Clinical Data Supports Adult Expansion Amidst Strong Q1 Revenue Growth
Executive Summary
- Fennec Pharmaceuticals presented four independent research studies at the 2026 ASCO Annual Meeting regarding PEDMARK (sodium thiosulfate injection).
- Research focuses on expanding clinical utility from pediatric to Adolescent and Young Adult (AYA) and adult populations.
- Key findings include significant reductions in cisplatin-induced ototoxicity in Japanese pediatric/AYA patients (16–24% hearing loss vs 56–63% historically).
- Evidence supports safety and feasibility of administration in adult head and neck cancer patients, specifically when administered ≥ six hours after cisplatin dosing.
- A retrospective case series of nine AYA/adult patients demonstrated feasible incorporation into oncology workflows without compromising antitumor activity.
- Presentation includes design for a randomized Phase 1 study evaluating cisplatin-based chemotherapy with or without sodium thiosulfate in men with metastatic Germ Cell Tumor (GCT).
Material Impact
- The news is consistent with the April 21, 2026 announcement regarding abstract acceptance and the December 2025 announcement of positive topline results from the Japan STS-J01 study.
- As the data was previously disclosed as "positive topline" in late 2025 and abstracts were accepted in April, this presentation is an expected follow-up rather than a surprise catalyst.
- The clinical validation supports the company's stated strategy of label expansion into adult populations, which represents a larger addressable market (~500k U.S. patients annually).
- While positive for long-term growth potential, it does not constitute immediate regulatory approval or new revenue streams compared to the Q1 2026 earnings release (May 14) which drove significant price appreciation.
- The news reinforces confidence in the commercialization strategy but lacks the "new" financial or regulatory milestone required for a Material - Positive rating given prior disclosures.
FRX · Price
Company Overview
- Company: Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX).
- Flagship Product: PEDMARK (sodium thiosulfate injection).
- Indication: FDA-approved for pediatric patients ≥1 month old with localized non-metastatic solid tumors to reduce cisplatin-induced ototoxicity.
- Development Status: Currently seeking label expansion into Adolescent/Young Adult (AYA) and adult populations based on real-world evidence and clinical trials.
- Commercial Strategy: "Project Ignite" sales force expansion targeting 5,000+ accounts; Fennec HEARS patient support hub driving adherence (~80%).
More from FENNEC PHARMACEUTICALS INC. J
May 14, 2026 · 06:30